Bruno Julianne — SEC insider filings
SEC reporting owner CIK 2019645. 11 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-05-24 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 4 filings — 6,801 shares, $336,100 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: sale of 3,366 shares @ $56.09 ($188,799) in CRISPR Therapeutics AG, filed 2024-06-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | Chief Operating Officer | 7 | — | 5 legs · 6,801 sh · $336,100 | 14 |
| Damora Therapeutics, Inc. (DMRA) | Director | 2 | — | — | 3 |
| InMed Pharmaceuticals Inc. (MTRI) | Director | 2 | — | — | 1 |
Insider filings — Bruno Julianne
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 3 | InMed Pharmaceuticals Inc. (MTRI) | Holdings only — no transactions reported | EDGAR |
| 2026-11-12 | 4 | InMed Pharmaceuticals Inc. (MTRI) | Grant/award (A): 37,000 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | Damora Therapeutics, Inc. (DMRA) | Grant/award (A): 37,313 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Galecto, Inc. (GLTO) | Option exercise (M): 129,000 @ $0 · Option exercise (M): 129 (derivative) @ $0 | EDGAR |
| 2025-03-24 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 3,750 · Sale (S): 1,714 @ $41.23 · Option exercise (M): 3,750 (derivative) | EDGAR |
| 2025-03-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 36,666 (derivative) @ $0 · Grant/award (A): 27,500 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 2,399 · Sale (S): 1,198 @ $42.42 · Option exercise (M): 435 · Sale (S): 190 @ $43.32 · Option exercise (M): 2,399 (derivative) · Option exercise (M): 435 (derivative) | EDGAR |
| 2025-02-19 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 650 · Sale (S): 333 @ $52.80 · Option exercise (M): 650 (derivative) | EDGAR |
| 2024-10-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 18,333 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 7,000 · Sale (S): 3,366 @ $56.09 · Option exercise (M): 7,000 (derivative) | EDGAR |
| 2024-05-24 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=2019645 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs